The long-term effect of the combination of estramustine and cyclophosphamide to castration resistant prostate cancer: A case report

Michihisa Saegusa, Shingo Nishimura, Kouhei Edamura, Kyouhei Kurose, Shin Ebara

Research output: Contribution to journalArticle

Abstract

A 66-year-old man was diagnosed as prostate cancer of T2aN1M0, GS4+5. After CAB, radical prostatectomy was performed, and hormonal therapy was continued after operation. However he gadually became nonrespondent. At the time PSA become 17.38 ng/ml, combined application of estramustine (EMP) and cyclophosphamide (CPA) was started. PSA decreased gradually, and became below 0.01 ng/ml 14 months later, there-fore both medicines were discontinued on the 24th month. Adverse effects were only slight bone-marrow suppression. After 41 months, PSA became 0.02 ng/ml, and bone abnormality by CT also improved. The longterm effect of EMP and CPA, to castration resistant prostate cancer patient was thus achieved.

Original languageEnglish
Pages (from-to)167-170
Number of pages4
JournalJapanese Journal of Clinical Urology
Volume66
Issue number2
Publication statusPublished - Feb 20 2012

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'The long-term effect of the combination of estramustine and cyclophosphamide to castration resistant prostate cancer: A case report'. Together they form a unique fingerprint.

  • Cite this